Production (Stage)
Perspective Therapeutics, Inc.
CATX
$2.39
-$0.12-4.78%
AMEX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -45.79% | -70.46% | -154.12% | -213.73% | -497.11% |
| Total Depreciation and Amortization | 288.52% | 321.29% | 93.47% | 91.25% | 99.31% |
| Total Amortization of Deferred Charges | 0.00% | 0.00% | -- | -- | -- |
| Total Other Non-Cash Items | 75.56% | 325.72% | 341.85% | 321.89% | 293.15% |
| Change in Net Operating Assets | -96.39% | 1,141.82% | 3,314.34% | 2,667.92% | 2,514.88% |
| Cash from Operations | -302.67% | 50.44% | 97.84% | 40.66% | 28.65% |
| Capital Expenditure | -402.85% | -4,975.93% | -3,720.79% | -1,046.97% | -2,075.71% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -100.00% | -100.00% | -100.00% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -233.49% | -824.75% | -239.11% | -581.67% | -543.60% |
| Cash from Investing | -267.74% | -998.25% | -361.19% | -1,126.70% | -1,202.32% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 24.62% | 29.41% | 14.29% | -51.43% | -333.33% |
| Issuance of Common Stock | -20.65% | 31,389.76% | 52,145.49% | 51,474.64% | 597,250.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 443,261.54% | 100.00% | 100.00% | 100.00% |
| Cash from Financing | -20.43% | 36,764.33% | 66,734.18% | 62,675.00% | 321,625.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -192.64% | 543.73% | 20,803.58% | 911.31% | 570.63% |